<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="162">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02289079</url>
  </required_header>
  <id_info>
    <org_study_id>1305m34041</org_study_id>
    <nct_id>NCT02289079</nct_id>
  </id_info>
  <brief_title>TAP Block With Liposomal Bupivacaine Versus Bupivacaine in Robotic Hysterectomy</brief_title>
  <official_title>Ultrasound Guided Subcostal Transversus Abdominis Plane (TAP) Block With Liposomal Bupivacaine vs Bupivacaine in Robotic Hysterectomy Patients: A Prospective Randomized Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Minnesota - Clinical and Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Minnesota - Clinical and Translational Science Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to compare pain control after robotic hysterectomy surgery using
      either liposomal bupivacaine or Bupivacaine when injected during a transversus abdominis
      plane (TAP) block. Robotic hysterectomy is when a patient is electively having robotic
      assisted removal of one's uterus. Both medications liposomal bupivacaine and Bupivacaine are
      standard of care in these types of surgeries.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment technique:

      The patient will be in the supine position. The transversus abdominis muscle layer will be
      identified with the ultrasound. Using sterile technique, skin infiltration with 2% lidocaine
      will occur, 2 cm medial to the ultrasound probe. An 22g Nerve block needle will then be
      inserted and advanced under ultrasound guidance until it is below the fascial covering of
      the transversus abdominis muscle layer. Gentle aspiration for air, or blood will be
      performed and either 30 cc of 0.25% bupivacaine with 1/200,000 parts epinephrine or 30 mL of
      liposomal bupivacaine mixed 1:1 with normal saline will be injected under ultrasound
      guidance. For each 5cc of local anesthetic injected, aspiration will be performed. Upon
      completion of the injection, the needle will then be removed. This will then be completed on
      the contralateral side. The patient will be monitored in the preoperative area until he/she
      is brought into the operating room for their procedure.

      When the operation is complete the patient will either be discharged home or brought to the
      ward where each day a member of the research team will evaluate the patient for signs of
      complications and ask the patient their minimum and maximum pain score.

      If patients have met criterion for discharge to home including pain &lt;4/10, independence of
      intravenous analgesia, and are stable for discharge medically, but are awaiting placement,
      the time of discharge for the purposes of the study will be the day they have met such
      criterion as opposed to the day of actual discharge, as this can vary depending on patient
      placement.

      If the patient is discharged prior to 72 hours post injection, then the patient will receive
      one phone call at 24 hours post injection, 48 hours post injection , and 72 hours post
      injection +/- 5 hours. During this phone call the patient will be asked about pain score,
      narcotic use, overall satisfaction via a recorded patient questionnaire, quality of recovery
      via a quality of recovery survey, and assessed if any adverse events have occurred.

      Adequate analgesia will be defined as &lt;3 VAS at rest, and if VAS is greater than 3
      adjustments in oral or intravenous pain medications will be given as determined by the
      nurse.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Post Operative Opioid Use</measure>
    <time_frame>0-72 hours after injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine if liposomal bupivacaine provides decreased narcotic use when compared to bupivacaine when injected in a TAP block</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numerical Rating Scale</measure>
    <time_frame>48-72 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>This was a measure of patient's reported pain on a 0-10 verbal numerical rating scale. 10 being worst pain. The maximal value for the time period 48-72 hours was chosen as the maximal pain during that time period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post Operative Length of Stay</measure>
    <time_frame>up to 30 days after surgery</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine if liposomal bupivacaine provides decreased length of stay when compared to bupivacaine when injected in a TAP block</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Satisfaction as Assessed Via Patient Survey</measure>
    <time_frame>assessed at 72 hours after injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine if liposomal bupivacaine improves quality of recovery post-operatively when compared to bupivacaine when injected in a TAP block via a patient survey either in person or via telephone.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Acute Pain</condition>
  <arm_group>
    <arm_group_label>liposomal bupivacaine TAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>these patients receive a subcostal TAP with liposomal bupivacaine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>bupivacaine TAP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These patients receive a subcostal TAP with bupivacaine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <arm_group_label>bupivacaine TAP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liposomal bupivacaine</intervention_name>
    <arm_group_label>liposomal bupivacaine TAP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  those who present for elective robotic assisted hysterectomy

        Exclusion Criteria:

          -  non english speaking

          -  chronic pain

          -  on opioids greater than 1 weeks

          -  chronic anticoagulation

          -  allergy to local anesthetics

          -  use of spinal or epidural for surgery

          -  lack of patient cooperation

          -  contraindication to regional anesthesia
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2015</verification_date>
  <lastchanged_date>December 11, 2015</lastchanged_date>
  <firstreceived_date>October 30, 2014</firstreceived_date>
  <firstreceived_results_date>December 11, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acute Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Liposomal Bupivacaine TAP</title>
          <description>these patients receive a subcostal TAP with liposomal bupivacaine
liposomal bupivacaine</description>
        </group>
        <group group_id="P2">
          <title>Bupivacaine TAP</title>
          <description>These patients receive a subcostal TAP with bupivacaine
Bupivacaine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Liposomal Bupivacaine TAP</title>
          <description>these patients receive a subcostal TAP with liposomal bupivacaine
liposomal bupivacaine</description>
        </group>
        <group group_id="B2">
          <title>Bupivacaine TAP</title>
          <description>These patients receive a subcostal TAP with bupivacaine
Bupivacaine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="25"/>
                <measurement group_id="B3" value="45"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="28"/>
                <measurement group_id="B2" value="30"/>
                <measurement group_id="B3" value="58"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="89.3" spread="25.1"/>
                <measurement group_id="B2" value="98.5" spread="34.2"/>
                <measurement group_id="B3" value="93.5" spread="30.2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Post Operative Opioid Use</title>
        <description>To determine if liposomal bupivacaine provides decreased narcotic use when compared to bupivacaine when injected in a TAP block</description>
        <time_frame>0-72 hours after injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>these patients receive a subcostal TAP with liposomal bupivacaine
liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>These patients receive a subcostal TAP with bupivacaine
Bupivacaine</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Post Operative Opioid Use</title>
            <description>To determine if liposomal bupivacaine provides decreased narcotic use when compared to bupivacaine when injected in a TAP block</description>
            <units>micrograms of fentanyl equivalents</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="24.9" lower_limit="0" upper_limit="86.7"/>
                  <measurement group_id="O2" value="51.7" lower_limit="0" upper_limit="249.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Numerical Rating Scale</title>
        <description>This was a measure of patient's reported pain on a 0-10 verbal numerical rating scale. 10 being worst pain. The maximal value for the time period 48-72 hours was chosen as the maximal pain during that time period.</description>
        <time_frame>48-72 hours</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>these patients receive a subcostal TAP with liposomal bupivacaine
liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>These patients receive a subcostal TAP with bupivacaine
Bupivacaine</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Numerical Rating Scale</title>
            <description>This was a measure of patient's reported pain on a 0-10 verbal numerical rating scale. 10 being worst pain. The maximal value for the time period 48-72 hours was chosen as the maximal pain during that time period.</description>
            <units>scores on a scale</units>
            <param>Median</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="3" lower_limit="0" upper_limit="8"/>
                  <measurement group_id="O2" value="5" lower_limit="0" upper_limit="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post Operative Length of Stay</title>
        <description>To determine if liposomal bupivacaine provides decreased length of stay when compared to bupivacaine when injected in a TAP block</description>
        <time_frame>up to 30 days after surgery</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>these patients receive a subcostal TAP with liposomal bupivacaine
liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>These patients receive a subcostal TAP with bupivacaine
Bupivacaine</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Post Operative Length of Stay</title>
            <description>To determine if liposomal bupivacaine provides decreased length of stay when compared to bupivacaine when injected in a TAP block</description>
            <units>Hours</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11" spread="9.1"/>
                  <measurement group_id="O2" value="17" spread="13.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Satisfaction as Assessed Via Patient Survey</title>
        <description>To determine if liposomal bupivacaine improves quality of recovery post-operatively when compared to bupivacaine when injected in a TAP block via a patient survey either in person or via telephone.</description>
        <time_frame>assessed at 72 hours after injection</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Liposomal Bupivacaine TAP</title>
            <description>these patients receive a subcostal TAP with liposomal bupivacaine
liposomal bupivacaine</description>
          </group>
          <group group_id="O2">
            <title>Bupivacaine TAP</title>
            <description>These patients receive a subcostal TAP with bupivacaine
Bupivacaine</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="28"/>
                  <measurement group_id="O2" value="29"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patient Satisfaction as Assessed Via Patient Survey</title>
            <description>To determine if liposomal bupivacaine improves quality of recovery post-operatively when compared to bupivacaine when injected in a TAP block via a patient survey either in person or via telephone.</description>
            <units>number satisfied with pain control</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                  <measurement group_id="O2" value="24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Liposomal Bupivacaine TAP</title>
          <description>these patients receive a subcostal TAP with liposomal bupivacaine
liposomal bupivacaine</description>
        </group>
        <group group_id="E2">
          <title>Bupivacaine TAP</title>
          <description>These patients receive a subcostal TAP with bupivacaine
Bupivacaine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jacob Hutchins</name_or_title>
      <organization>University of MInnesota</organization>
      <phone>6126249990</phone>
      <email>hutc0079@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
